Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.56 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | RAF1 | P04049 | 5/20 | 0.33 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.31 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.31 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.31 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.31 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.31 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | COMT | P21964 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12370923 | 0.69 | — | — | |
| SCHEMBL2375615 | 0.67 | TP53 (0.63) | HCAR2TP53MAPTPOLBRAF1 | |
| SCHEMBL5952118 | 0.66 | METAP1 (0.51) | HCAR2TP53MAPT | |
| SCHEMBL16675881 | 0.66 | HCAR2 (0.49) | HCAR2HCAR3TP53MAPTPOLB | |
| SCHEMBL11888038 | 0.64 | CA12 (0.51) | HCAR2HCAR3TP53MAPTPOLB | |
| SCHEMBL11886212 | 0.64 | SMN1; SMN2 (0.61) | HCAR2TP53MAPTPOLBRAF1 | |
| SCHEMBL2609449 | 0.64 | CRHBP (0.51) | HCAR2TP53MAPTPOLBRAF1 | |
| SCHEMBL786337 | 0.63 | HCAR2 (0.50) | HCAR2HCAR3TP53MAPTPOLB | |
| SCHEMBL4458826 | 0.63 | HCAR2 (0.46) | HCAR2HCAR3TP53MAPTPOLB | |
| SCHEMBL101638 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139628-A1 | Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists | ARENA PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | US | claimed |
| CN-101076331-A | Compositions comprising nicotinic acid receptor partial agonists for the treatment of rubeosis and lipid-related disorders | ARENA PHARM INC (US) | 2007-11-21 | — | — | CN | claimed |
| EP-1811996-A1 | COMPOSITIONS FOR TREATING FLUSHING AND LIPID-ASSOCIATED DISORDERS COMPRISING NIACIN RECEPTOR PARTIAL AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | claimed |
| WO-2006052569-A1 | COMPOSITIONS FOR TREATING FLUSHING AND LIPID-ASSOCIATED DISORDERS COMPRISING NIACIN RECEPTOR PARTIAL AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20080139628-A1 | Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists | ARENA PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139628-A1 | Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists | ARENA PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139628-A1 | Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists | ARENA PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| CN-101076331-A | Compositions comprising nicotinic acid receptor partial agonists for the treatment of rubeosis and lipid-related disorders | ARENA PHARM INC (US) | 2007-11-21 | — | — | CN | disclosed |
| EP-1811996-A1 | COMPOSITIONS FOR TREATING FLUSHING AND LIPID-ASSOCIATED DISORDERS COMPRISING NIACIN RECEPTOR PARTIAL AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052569-A1 | COMPOSITIONS FOR TREATING FLUSHING AND LIPID-ASSOCIATED DISORDERS COMPRISING NIACIN RECEPTOR PARTIAL AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139628-A1 | Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists | FFAR1, FFAR2, FFAR3 | HCAR2 11/4885HCAR3 19/4885TP53 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.